Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2017 (2017), Article ID 7834702, 7 pages
https://doi.org/10.1155/2017/7834702
Case Report

Complete Response after Treatment with Neoadjuvant Chemoradiation with Prolonged Chemotherapy for Locally Advanced, Unresectable Adenocarcinoma of the Pancreas

1Department of Medicine, Division of Hematology/Oncology, Drexel University College of Medicine, Philadelphia, PA 19102, USA
2Department of Surgery, Division of Surgical Oncology, Drexel University College of Medicine, Philadelphia, PA 19102, USA
3Department of Pathology & Laboratory Medicine, Drexel University College of Medicine, Philadelphia, PA 19102, USA
4Department of Radiation Oncology, Drexel University College of Medicine, Philadelphia, PA 19102, USA

Correspondence should be addressed to Wilbur B. Bowne

Received 17 January 2017; Accepted 26 February 2017; Published 8 March 2017

Academic Editor: Francesco A. Mauri

Copyright © 2017 Tiffany A. Pompa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Carpelan-Holmström, S. Nordling, E. Pukkala et al., “Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry,” Gut, vol. 54, no. 3, pp. 385–387, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. C. R. Ferrone, M. F. Brennan, M. Gonen et al., “Pancreatic adenocarcinoma: the actual 5-year survivors,” Journal of Gastrointestinal Surgery, vol. 12, no. 4, pp. 701–706, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. E. M. O'Reilly, “Pancreatic adenocarcinoma: new strategies for success,” Gastrointestinal Cancer Research, vol. 3, no. 2, supplement 1, pp. S11–S15, 2009. View at Google Scholar
  4. D. B. Evans, “Resectable pancreatic cancer: the role for neoadjuvant/preoperative therapy,” HPB, vol. 8, no. 5, pp. 365–368, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. W. Small Jr., J. Berlin, G. M. Freedman et al., “Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial,” Journal of Clinical Oncology, vol. 26, no. 6, pp. 942–947, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. V. Heinemann, M. Haas, and S. Boeck, “Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer,” Annals of Oncology, vol. 24, no. 10, pp. 2484–2492, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. Network NCC, “Pancreatic Adenocarcinoma (Version 2.2016),” 2016, https://www.nccn.org/professionals/physician_gls/PDF/pancreatic.pdf.
  8. C. R. Ferrone, G. Marchegiani, T. S. Hong et al., “Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer,” Annals of Surgery, vol. 261, no. 1, pp. 12–17, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Tsai, K. K. Christians, P. S. Ritch et al., “Multimodality therapy in patients with borderline resectable or locally advanced pancreatic cancer: importance of locoregional therapies for a systemic disease,” Journal of Oncology Practice, vol. 12, no. 10, pp. 915–923, 2016. View at Publisher · View at Google Scholar
  10. E. Sadot, A. Doussot, E. M. O’Reilly et al., “FOLFIRINOX induction therapy for stage 3 pancreatic adenocarcinoma,” Annals of Surgical Oncology, vol. 22, no. 11, pp. 3512–3521, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Lorenzen, P. Thuss-Patience, S. E. Al-Batran et al., “Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy,” Annals of Oncology, vol. 24, no. 8, pp. 2068–2073, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. Q. Zhao, A. Rashid, Y. Gong et al., “Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis,” Annals of Diagnostic Pathology, vol. 16, no. 1, pp. 29–37, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Conroy, F. Desseigne, M. Ychou et al., “FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer,” The New England Journal of Medicine, vol. 364, no. 19, pp. 1817–1825, 2011. View at Google Scholar
  14. C. Yoo, J. Y. Hwang, J.-E. Kim et al., “A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer,” British Journal of Cancer, vol. 101, no. 10, pp. 1658–1663, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Cereda, M. Reni, A. Rognone et al., “XELIRI or FOLFIRI as salvage therapy in advanced pancreatic cancer,” Anticancer Research, vol. 30, no. 11, pp. 4785–4790, 2010. View at Google Scholar · View at Scopus
  16. S. M. Strasberg, J. A. Drebin, and D. Linehan, “Radical antegrade modular pancreatosplenectomy,” Surgery, vol. 133, no. 5, pp. 521–527, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. J. G. Grossman, R. C. Fields, W. G. Hawkins, and S. M. Strasberg, “Single institution results of radical antegrade modular pancreatosplenectomy for adenocarcinoma of the body and tail of pancreas in 78 patients,” Journal of Hepato-Biliary-Pancreatic Sciences, vol. 23, no. 7, pp. 432–441, 2016. View at Publisher · View at Google Scholar · View at Scopus
  18. G. R. Varadhachary, E. P. Tamm, J. L. Abbruzzese et al., “Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy,” Annals of Surgical Oncology, vol. 13, no. 8, pp. 1035–1046, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. D. B. Evans, M. B. Farnell, K. D. Lillemoe, C. Vollmer Jr., S. M. Strasberg, and R. D. Schulick, “Surgical treatment of resectable and borderline resectable pancreas cancer: expert consensus statement,” Annals of Surgical Oncology, vol. 16, no. 7, pp. 1736–1744, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Gillen, T. Schuster, C. M. Z. Büschenfelde, H. Friess, and J. Kleeff, “Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages,” PLoS Medicine, vol. 7, no. 4, Article ID e1000267, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. P. J. Hosein, J. Macintyre, C. Kawamura et al., “A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma,” BMC Cancer, vol. 12, article 199, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. M. H. G. Katz, J. B. Fleming, P. Bhosale et al., “Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators,” Cancer, vol. 118, no. 23, pp. 5749–5756, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. E. A. Eisenhauer, P. Therasse, J. Bogaerts et al., “New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1),” European Journal of Cancer, vol. 45, no. 2, pp. 228–247, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Picchio, E. Giovannini, P. Passoni et al., “Role of PET/CT in the clinical management of locally advanced pancreatic cancer,” Tumori, vol. 98, no. 5, pp. 643–651, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. S. T. Chang, K. A. Goodman, G. P. Yang, and A. C. Koong, “Stereotactic body radiotherapy for unresectable pancreatic cancer,” Frontiers of Radiation Therapy and Oncology, vol. 40, pp. 386–394, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. Z. Li, H. Shang, X. Zhang, H. Zhang, J. Bao, and C. Hao, “Surgical treatment for locally advanced pancreatic cancer localized in the pancreatic body and tail (Report of 11 cases),” International Journal of Clinical and Experimental Medicine, vol. 8, no. 3, pp. 4676–4681, 2015. View at Google Scholar · View at Scopus
  27. A. R. Sasson, R. W. Wetherington, J. P. Hoffman et al., “Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcome,” International Journal of Gastrointestinal Cancer, vol. 34, no. 2-3, pp. 121–127, 2004. View at Google Scholar · View at Scopus
  28. J.-L. Lee, S. C. Kim, J.-H. Kim et al., “Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma,” Surgery, vol. 152, no. 5, pp. 851–862, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. K. T. Chen, K. Devarajan, B. N. Milestone et al., “Neoadjuvant chemoradiation and duration of chemotherapy before surgical resection for pancreatic cancer: does time interval between radiotherapy and surgery matter?” Annals of Surgical Oncology, vol. 21, no. 2, pp. 662–669, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. B. G. Czito, C. G. Willett, J. W. Clark, and C. F. Del Castillo, “Current perspectives on locally advanced pancreatic cancer,” Oncology, vol. 14, no. 11, pp. 1535–1545, 2000. View at Google Scholar · View at Scopus
  31. L. Rahib, B. D. Smith, R. Aizenberg, A. B. Rosenzweig, J. M. Fleshman, and L. M. Matrisian, “Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the united states,” Cancer Research, vol. 74, no. 11, pp. 2913–2921, 2014. View at Publisher · View at Google Scholar · View at Scopus